fms related receptor tyrosine kinase 3
Last updated 5 Jul 2022
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The FLT3 gene provides instructions for making a protein called fms-like tyrosine kinase 3 (FLT3), which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction. The FLT3 protein is found in the outer membrane of certain cell types where a specific protein called FLT3 ligand, or FL, can attach (bind) to it. This binding turns on (activates) the FLT3 protein, which subsequently activates a series of proteins inside the cell that are part of multiple signaling pathways. The signaling pathways stimulated by the FLT3 protein control many important cellular processes such as the growth and division (proliferation) and survival of cells, particularly of early blood cells called hematopoietic progenitor cells.
Video picks for GenesVideo library
Normal function
The FLT3 gene provides instructions for making a protein called fms-like tyrosine kinase 3 (FLT3), which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction. The FLT3 protein is found in the outer membrane of certain cell types where a specific protein called FLT3 ligand, or FL, can attach (bind) to it. This binding turns on (activates) the FLT3 protein, which subsequently activates a series of proteins inside the cell that are part of multiple signaling pathways. The signaling pathways stimulated by the FLT3 protein control many important cellular processes such as the growth and division (proliferation) and survival of cells, particularly of early blood cells called hematopoietic progenitor cells.
Conditions referring to this gene or chromosome
Other names
CD135
CD135 antigen
fetal liver kinase 2
FL cytokine receptor
FLK-2
FLK2
FLT3_HUMAN
fms-like tyrosine kinase 3
fms-related tyrosine kinase 3
growth factor receptor tyrosine kinase type III
receptor-type tyrosine-protein kinase FLT3
stem cell tyrosine kinase 1
STK-1
STK1
Patient picks for Genes

Heart health and blood vessels
Deep vein thrombosis
A deep vein thrombosis (DVT) is a blood clot in a vein. Blood clots in veins most often occur in the legs but can occur elsewhere in the body, including the arms. This leaflet is about blood clots in leg veins. The most common cause of a blood clot developing in a vein is immobility. A complication can occur in some cases where part of the blood clot breaks off and travels to the lung (pulmonary embolus). This is usually prevented if you are given anticoagulation treatment.
by Dr Toni Hazell, FRCGP

Travel and vaccinations
Dengue
Dengue (which used to be called dengue fever) is a viral illness which is very common in the tropics and subtropics. It is usually a flu-like illness lasting under a week but it can sometimes be very serious, even fatal.
by Dr Philippa Vincent, MRCGP

Travel and vaccinations
Altitude sickness
Altitude sickness can affect people who climb or travel (ascend) to more than 2500 metres (8,000 feet) altitude, particularly if they ascend too quickly.
by Dr Philippa Vincent, MRCGP

Chest and lungs
Tuberculosis
Tuberculosis (TB) is an infection with a germ (bacterium) called Mycobacterium tuberculosis. If you have symptoms, or a doctor can find signs of the infection when examining you, this is known as active tuberculosis. If you have TB infection without any signs or symptoms, this is known as latent TB.
by Dr Colin Tidy, MRCGP

Travel and vaccinations
Jet lag
Jet lag occurs after travelling rapidly across several time zones, because the body's internal clock has not adjusted to the required sleep-wake cycle in the new time zone. Jet lag causes physical and psychological symptoms, the severity of which increases with the number of time zones crossed and direction of travel. Eastward travel, when hours are 'gained' is associated with worse jet lag than westward travel, when hours are 'lost.'
by Dr Hayley Willacy, FRCGP

Travel and vaccinations
Malaria
Malaria is a very serious infection which results from a bite from an infected mosquito. The most common symptoms are high temperature (fever) and a flu-like illness. The symptoms of malaria can occur up to a year after being bitten in an area in which malaria is present. Prompt treatment for malaria is essential as, without treatment, it can be fatal. This leaflet gives general information about malaria and its treatment.
by Dr Philippa Vincent, MRCGP
Related patient information and medicines

Patient information leaflet
Mouth cancer
Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Patient information leaflet
Chronic myeloid leukaemia
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Mastocytosis and mast cell disorders
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
Liver function tests
They include substances that are made in the liver or affected by the health of the liver cells, chemicals which are processed or excreted by the liver, and hormones that the liver makes. What are liver function tests used for. Liver function tests are aimed at giving a picture of the 'state' of your liver. They are a sensitive way of looking for.

Patient information leaflet
Deep vein thrombosis
Raise the foot of the bed a few inches if it is comfortable to sleep like this. This is so your foot and calf are slightly higher than your hip when you are asleep. Other treatments Sometimes other treatments may be considered - for example: Clot-busting (thrombolytic) therapy with medicines such as streptokinase or urokinase. These may help to.

Patient information leaflet
Can I take Carbocisteine and Omega-3 together?
...supplementsOmega-3 fatty acids are nutrients used by the body for various functions, including heart and brain health. Our Medicines Interaction Checker helps you check whether your prescriptions, over-the-counter medicines, and supplements are safe to take together. Simply search for your medicines to see potential interactions and what to do.
Further reading and references
- fms related receptor tyrosine kinase 3; MedlinePlus, National Library of Medicine.
- Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Muller-Tidow C, Serve H. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005 Jul 1;106(1):265-73. doi: 10.1182/blood-2004-07-2942. Epub 2005 Mar 15.
- Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
- Dolence JJ, Gwin KA, Shapiro MB, Medina KL. Flt3 signaling regulates the proliferation, survival, and maintenance of multipotent hematopoietic progenitors that generate B cell precursors. Exp Hematol. 2014 May;42(5):380-393.e3. doi: 10.1016/j.exphem.2014.01.001. Epub 2014 Jan 18.
- Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 1;100(5):1532-42. doi: 10.1182/blood-2002-02-0492.
- Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
- Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020 Feb;111(2):312-322. doi: 10.1111/cas.14274. Epub 2019 Dec 30.
- Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002 Apr 11;21(16):2555-63. doi: 10.1038/sj.onc.1205332.
- Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154.
- Lewis JFM, Daver NG, Robinson NJ, Pandya BJ, Pierre-Louis B, Monir S, Sierra J. Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis. Cancer Med. 2025 Sep;14(18):e71205. doi: 10.1002/cam4.71205.
- Li L, Piloto O, Kim KT, Ye Z, Nguyen HB, Yu X, Levis M, Cheng L, Small D. FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol. 2007 Apr;137(1):64-75. doi: 10.1111/j.1365-2141.2007.06525.x.
- Ningombam A, Verma D, Kumar R, Singh J, Ali MS, Pandey AK, Singh I, Bakhshi S, Sharma A, Pushpam D, Palanichamy JK, Tanwar P, Singh AR, Chopra A. Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in cytogenetically normal adult AML patients. Am J Blood Res. 2023 Feb 15;13(1):28-43. eCollection 2023.
- Niparuck P, Limsuwanachot N, Pukiat S, Chantrathammachart P, Rerkamnuaychoke B, Magmuang S, Phusanti S, Boonyawat K, Puavilai T, Angchaisuksiri P, Ungkanont A, Chuncharunee S. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. Exp Hematol Oncol. 2019 Jan 30;8:3. doi: 10.1186/s40164-019-0127-z. eCollection 2019.
- Pastore F, Pastore A, Rothenberg-Thurley M, Metzeler KH, Ksienzyk B, Schneider S, Bohlander SK, Braess J, Sauerland MC, Gorlich D, Berdel WE, Wormann B, von Bergwelt-Baildon MS, Hiddemann W, Spiekermann K. Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis. Cancer. 2022 Dec 15;128(24):4213-4222. doi: 10.1002/cncr.34495. Epub 2022 Oct 22.
- Schwede M, Rodriguez G, Kennedy VE, Henry S, Wood D, Mannis GN, Majeti R, Chen JH, Bendavid E, Zhang TY. The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data. Haematologica. 2025 Jul 1;110(7):1634-1638. doi: 10.3324/haematol.2024.286695. Epub 2025 Feb 6. No abstract available.
- Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001 Apr 15;97(8):2434-9. doi: 10.1182/blood.v97.8.2434.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

